Media update

CAPRISA 004 trial results - Microbicide gel safe and effective in preventing HIV infection among women

The HIV Prevention Research Unit (HPRU) on behalf of the Medical Research Council congratulates the CAPRISA 004 trial team on successfully completing the phase IIb trial of 1% tenofovir gel in the prevention of HIV among women. The trial demonstrated a 39% reduction of HIV among women using 1% tenofovir gel within 12 hours before after sex. This is a long awaited scientific breakthrough for the microbicide field and for antiretroviral prophylaxis. Results of the CAPRISA 004 trial will have to be confirmed by another trial before tenofovir can be widely available as an HIV prevention option. The HPRU is currently participating in the VOICE (Vaginal and Oral Intervention to Control the Epidemic) trial which is testing 1% tenofovir gel for daily application against placebo. The trial is also testing oral tenofovir and Truvada against placebo in the same trial. The results are expected 2012. Other trials of antiretrovirals for HIV prevention are ongoing in various populations around the world.

CONTACT:

For: Prof. Gita Ramjee
Unit Director
Please contact:                                                                                                                                               
Ms Neetha S. Morar                                                      
Research and QA/QC Manager  
Tel. +27 31 242 3630
E-Mail: neetha.morar@mrc.ac.za

Dr Shayhana Ganesh
Clinical Manager & Principal Investigator
Tel. +27 31 242 3671
E-Mail: shay.ganesh@mrc.ac.za